These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30124524)

  • 1. Theratyping in cystic fibrosis.
    Crawford KJ; Downey DG
    Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The march towards CFTR modulator access for all people with CF: The end of the beginning.
    VanDevanter DR
    J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
    [No Abstract]   [Full Text] [Related]  

  • 4. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
    Mitchell RM; Jones AM; Barry PJ
    Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomically-guided therapies: A new era for cystic fibrosis.
    Fajac I; Girodon E
    Arch Pediatr; 2020 Feb; 27 Suppl 1():eS41-eS44. PubMed ID: 32172937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ion Channel Modulators in Cystic Fibrosis.
    Gentzsch M; Mall MA
    Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Specific Variants Causing Cystic Fibrosis.
    Cutting GR
    JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
    [No Abstract]   [Full Text] [Related]  

  • 13. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezacaftor for the treatment of cystic fibrosis.
    Sala MA; Jain M
    Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
    Mall MA; Mayer-Hamblett N; Rowe SM
    Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
    Eckford PDW; McCormack J; Munsie L; He G; Stanojevic S; Pereira SL; Ho K; Avolio J; Bartlett C; Yang JY; Wong AP; Wellhauser L; Huan LJ; Jiang JX; Ouyang H; Du K; Klingel M; Kyriakopoulou L; Gonska T; Moraes TJ; Strug LJ; Rossant J; Ratjen F; Bear CE
    J Cyst Fibros; 2019 Jan; 18(1):35-43. PubMed ID: 29685812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
    Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
    Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
    Heltshe SL; Cogen J; Ramos KJ; Goss CH
    Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.